Atomic description of immune complex that causes heparin-induced thrombocytopenia

Patent metadata

Field	Value
Publication number	US-11435362-B2
Application number	US-201916446902-A
Country	US
Kind code	B2
Filing date	Jun 20, 2019
Priority date	Nov 6, 2014
Publication date	Sep 6, 2022
Grant date	Sep 6, 2022

Abstract

The present invention provides a humanized antibody or antibody fragment comprising (a) a humanized light chain comprising 1) Complementarity Determining Region (CDR)-L1, the sequence of which is identical to the sequence of SEQ ID NO: 3; 2) CDR-L2, the sequence of which is identical to the sequence of SEQ ID NO: 4; and 3) CDR-L3, the sequence of which is identical to the sequence of SEQ ID NO: 5, and (b) a humanized heavy chain comprising 1) CDR-H1, the sequence of which is identical to the sequence of SEQ ID NO: 6; 2) CDR-H2, the sequence of which is identical to the sequence of SEQ ID NO: 7; and 3) CDR-H3, the sequence of which is identical to the sequence of SEQ ID NO: 8, as well as methods for treating, diagnosing, and monitoring the progression of HIT. The present invention also provides methods for assessing the antigenicity and ability to cause HIT of anionic anticoagulants. The present invention also provides a mutant protein which has the same amino acid sequence of a wild type PF4 monomer except that (i) at least one amino acid of the wild type PF4 monomer has been deleted, (ii) at least one amino acid of the wild type PF4 monomer has been replaced by another amino acid, or (iii) a combination of such changes has been made. The present invention also provides methods of treating or reducing the likelihood of HIT, treating angiogenesis, treating abnormal cell growth, or affecting coagulation pathologies that lead to thrombus formation, by administering such mutant proteins to a patient.

First claim

What is claimed is:

1. A mutant platelet factor 4 (PF4) monomer comprising amino acids 9 through 70 of SEQ ID NO: 11 and having a serine at amino acid position 9 and glutamic acid at amino acid position 50 relative to SEQ ID NO: 11, wherein the mutant PF4 monomer further comprises at least one amino acid mutation selected from the group consisting of L11V and L55R relative to the amino acid sequence of SEQ ID NO: 11.

2. The mutant PF4 monomer of claim 1 , wherein the N-terminal amino acid residue of the mutant PF4 monomer is amino acid at position 9 of SEQ ID NO: 15.

3. A method for treating a subject afflicted with heparin-induced thrombocytopenia (HIT), the method comprising administering to the subject an effective amount of the mutant platelet factor 4 (PF4) monomer of claim 1 , wherein the administering the PF4 monomer interferes with PF4 tetramer oligomerization, thereby treating the HIT.

4. The mutant PF4 monomer of claim 1 , wherein the mutant PF4 monomer consists of amino acids 9 through 70 of SEQ ID NO: 11 having a serine at amino acid position 9 and glutamic acid at amino acid position 50 relative to SEQ ID NO: 11 and at least one amino acid mutation selected from the group consisting of L11V and L55R relative to the amino acid sequence of SEQ ID NO: 11.

5. A mutant PF4 monomer comprising amino acids 9 through 70 of SEQ ID NO: 11, a K50E substitution relative to the amino acid sequence of SEQ ID NO: 11, and at least one amino acid mutation selected from the group consisting of Q9S, L11V, and L55R relative to the amino acid sequence of SEQ ID NO: 11, wherein the N-terminal amino acid residue of the mutant PF4 monomer is amino acid at position 9 of SEQ ID NO: 15.

6. A mutant PF4 monomer comprising amino acids 9 through 70 of SEQ ID NO: 11, a K50E substitution relative to the amino acid sequence of SEQ ID NO: 11, and at least one amino acid mutation selected from the group consisting of Q9S, L11V, and L55R relative to the amino acid sequence of SEQ ID NO: 11.

7. A method for treating a subject afflicted with heparin-induced thrombocytopenia (HIT), the method comprising administering to the subject an effective amount of a mutant platelet factor 4 (PF4) monomer comprising amino acids 9 through 70 of SEQ ID NO: 11, a K50E substitution relative to the amino acid sequence of SEQ ID NO: 11, and at least one amino acid mutation selected from the group consisting of Q9S, L11V, and L 55 R relative to the amino acid sequence of SEQ ID NO: 11,
wherein the administering the PF4 monomer interferes with PF4 tetramer oligomerization, thereby treating the HIT.

8. A mutant PF4 monomer consisting of amino acids 9 through 70 of SEQ ID NO: 11, having a K50E substitution relative to the amino acid sequence of SEQ ID NO: 11 and having at least one amino acid mutation selected from the group consisting of Q9S, L11V, and L55R relative to the amino acid sequence of SEQ ID NO: 11.

Assignees

• Univ Pennsylvania

Inventors

• Greene Mark I
• Cines Douglas B
• Cai Zheng
• Zhu Zhiqiang

Classifications

• G01N2800/52

  Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis · CPC title

• A61K2039/505

  comprising antibodies · CPC title

• G01N2800/222

  Platelet disorders · CPC title

• G01N33/6863 Primary

  Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors · CPC title

• G01N33/86

  involving blood coagulating time {or factors, or their receptors} · CPC title